Citadel Advisors
PRPH

Citadel Advisors’s ProPhase Labs PRPH Stock Holding History

Citadel Advisors’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-600
Closed -$25.1K – 15010
2024
Q2 		$25.1K Buy
600
+500
+500% +$26.2K ﹤0.01% 12438
2024
Q1 		$6.47K Buy
+100
New +$5.07K ﹤0.01% 13668
2023
Q4 		– Sell
-440
Closed -$19.2K – 15022
2023
Q3 		$19.2K Sell
440
-1,240
-74% -$72.6K ﹤0.01% 12657
2023
Q2 		$122K Buy
1,680
+720
+75% +$58.6K ﹤0.01% 10631
2023
Q1 		$73.2K Sell
960
-310
-24% -$25K ﹤0.01% 11672
2022
Q4 		$122K Sell
1,270
-620
-33% -$67K ﹤0.01% 10927
2022
Q3 		$213K Buy
+1,890
New +$220K ﹤0.01% 10292
2022
Q1 		– Sell
-1,320
Closed -$95K – 14364
2021
Q4 		$95K Buy
1,320
+300
+29% +$18.7K ﹤0.01% 12769
2021
Q3 		$53K Buy
+1,020
New +$60.8K ﹤0.01% 13345
2021
Q2 		– Sell
-1,600
Closed -$118K – 14254
2021
Q1 		$118K Buy
+1,600
New +$154K ﹤0.01% 12321

Other funds holding PRPH

SC
Sykon Capital Harrison, New York $300M AUM 16.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $412M AUM 15.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's PRPH Position: Q3 2024 in Review

Citadel Advisors sold out of ProPhase Labs (PRPH) in Q3 2024, closing a stake of 380 shares — an estimated $15.9K sold.

Citadel Advisors first reported a position in PRPH in Q4 2013 and held it in 20 quarters. The position peaked at $204K in Q4 2021. 27 funds tracked by Wall St. Rank hold PRPH as of Q3 2024.

  • Citadel Advisors reported no remaining ProPhase Labs position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 380 ProPhase Labs shares in Q3 2024, an estimated $15.9K.
  • Citadel Advisors first reported a position in ProPhase Labs in Q4 2013 and held it in 20 quarters.
  • Citadel Advisors's ProPhase Labs position peaked at $204K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held ProPhase Labs as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.